Luana Calabrò

High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients

Mariantonia Logozzi, Angelo De Milito, Luana Lugini et al. · PLoS ONE · 2009 · 966 citations · Full text

Medicine, Cell Biology, Oncology +17

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

Michele Maio, Arnaud Scherpereel, Luana Calabrò et al. · The Lancet Oncology · 2017 · 424 citations

Medicine, Oncology, Pharmacotherapy +11

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Fabrice Barlési, Johan Vansteenkiste, David R. Spigel et al. · The Lancet Oncology · 2018 · 397 citations

Medicine, Oncology, Pharmacology +11

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Luana Calabrò, Aldo Morra, Ester Fonsatti et al. · The Lancet Oncology · 2013 · 354 citations

Medicine, Oncology, Pharmacology +11

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Anna Maria Di Giacomo, Riccardo Danielli, Massimo Guidoboni et al. · Cancer Immunology Immunotherapy · 2009 · 280 citations · Full text

Life Sciences, Immunology, Oncology +17